Comprehensive Ayurvedic Management of Hepatic Fibrosis (Grade III): A Case Report

Authors

  • Sangita Halder
  • Avishek Mishra All India Institute of Ayurveda
  • Subhajit Pahari
  • Shreyanti Nansi
  • Nabanita Chakrabarty
  • Tapas Bhaduri

DOI:

https://doi.org/10.70066/jahm.v13i10.2288

Keywords:

Ayurveda, Case report, Hepatic fibrosis

Abstract

Background: The prevalence of hepatic fibrosis is increasing worldwide, with significant geographic variation. It is necessary to better understand the risk factors and how to prevent and mitigate the disease worldwide to combat the advanced stage of fibrosis and its complications. In conventional treatment, targeting the underlying cause is often insufficient, and there is non-specific drug delivery, resulting in failure of antifibrotic drugs. Clinical findings: A 33-year-old male patient complained of general weakness, indigestion, loss of appetite, and distension of the abdomen. Radiological findings revealed Grade III hepatic fibrosis, and biochemical investigations showed abnormalities in lipid profile and altered liver enzyme levels. Intervention: He was treated with Sarphonka Swaras Ghan, Bhoomi Amla Swaras Ghan, Liv52 HB, Hridton, Triglize, and Haritaki Churna for five months, along with Diet and lifestyle modifications. Outcome: After five months of treatment, marked improvement was seen in appetite, fatigue level, digestion, and bowel habits. Liver was normal in size, contour, and echotexture (Grade III fatty infiltration before treatment) in Ultrasonography of the whole abdomen, and reduced from moderate (Grade III [F3]) to mild hepatic fibrosis(Grade I [F1]) in liver elastography (Metavir value-10.90 Kpa to 5.0 Kpa). Conclusion: A case of Hepatic fibrosis was effectively treated, associated with improvement through Ayurveda. The findings suggest the effectiveness and good safety tolerance of Ayurvedic interventions in managing hepatic fibrosis. This case report highlights the potential of using Ayurvedic treatment in larger-scale clinical studies for hepatic fibrosis.

References

Jiao J, Friedman SL, Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol. 2009 May;25(3):223-9. doi: 10.1097/mog.0b013e3283279668. PMID: 19396960; PMCID: PMC2883289.

Popper H, Uenfriend S. Hepatic fibrosis. Correlation of biochemical and morphologic investigations. Am J Med. 1970 Nov;49:707-21. doi: 10.1016/s0002-9343(70)80135-8. PMID: 4924592.

Albanis E, Friedman SL. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis. 2001 May;5(2):315-34, v-vi. doi: 10.1016/s1089-3261(05)70168-9. PMID: 11385966.

Soyer MT, Ceballos R, Aldrete JS. Reversibility of severe hepatic damage caused by jejunoileal bypass after re-establishment of normal intestinal continuity. Surgery. 1976 May;79(5):601-4. PMID: 1265672.

Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005 Feb;115(2):209-18. doi: 10.1172/JCI24282. Erratum in: J Clin Invest. 2005 Apr;115(4):1100. PMID: 15690074; PMCID: PMC546435.

Gora RH, Baxla SL, Kerketta P, Patnaik S, Roy BK. Hepatoprotective activity of Tephrosia purpurea against arsenic induced toxicity in rats. Indian J Pharmacol. 2014 Mar-Apr;46(2):197-200. doi: 10.4103/0253-7613.129317. PMID: 24741193; PMCID: PMC3987190.

Taylor L, Piedra C. 2nd ed. United States: Prima Publishing; 1998. “Stone Breaker” (Phyllanthus niruri), Herbal Secrets of the Rainforest.

Kumar S, Singh A, Kumar B. Identification and characterization of phenolics and terpenoids from ethanolic extracts of Phyllanthus species by HPLC-ESI-QTOF-MS/MS. J Pharm Anal. 2017 Aug;7(4):214-222. doi: 10.1016/j.jpha.2017.01.005. Epub 2017 January 18. PMID: 29404041; PMCID: PMC5790687.

Kassuya CA, Leite DF, de Melo LV, Rehder VL, Calixto JB. Anti-inflammatory properties of extracts, fractions and lignans isolated from Phyllanthus amarus. Planta Med. 2005 Aug;71(8):721-6. doi: 10.1055/s-2005-871258. PMID: 16142635.

Hassan Bulbul MR, Uddin Chowdhury MN, Naima TA, Sami SA, Imtiaj MS, Huda N, Uddin MG. A comprehensive review on the diverse pharmacological perspectives of Terminalia chebula Retz. Heliyon. 2022 Aug 14;8(8):e10220. doi: 10.1016/j.heliyon.2022.e10220. PMID: 36051270; PMCID: PMC9424961.

Choi MK, Kim HG, Han JM, Lee JS, Lee JS, Chung SH, Son CG. Hepatoprotective Effect of Terminalia chebula against t-BHP-Induced Acute Liver Injury in C57/BL6 Mice. Evid Based Complement Alternat Med. 2015;2015:517350. doi: 10.1155/2015/517350. Epub 2015 January 26. PMID: 25691908; PMCID: PMC4321673.

Kantharia C, Kumar M, Jain MK, Sharma L, Jain L, Desai A. Hepatoprotective Effects of Liv.52 in Chronic Liver Disease Preclinical, Clinical, and Safety Evidence: A Review. Gastroenterology Insights. 2023; 14(3):293-308. https://doi.org/10.3390/gastroent14030021

Parvez MK, Al-Dosari MS, Arbab AH, Niyazi S. The in vitro and in vivo anti-hepatotoxic, anti-hepatitis B virus and hepatic CYP450 modulating potential of Cyperus rotundus. Saudi Pharm J. 2019 May;27(4):558-564. doi: 10.1016/j.jsps.2019.02.003. Epub 2019 February 05. PMID: 31061625; PMCID: PMC6488921.

Parasuraman S, Kumar E, Kumar A, Emerson S. Free radical scavenging property and diuretic effect of triglize, a polyherbal formulation in experimental models. J Pharmacol Pharmacother. 2010 Jan;1(1):38-41. doi: 10.4103/0976-500X.64535. PMID: 21808589; PMCID: PMC3142756.

Soleimani D, Ranjbar G, Rezvani R, Goshayeshi L, Razmpour F, Nematy M. Dietary patterns in relation to hepatic fibrosis among patients with nonalcoholic fatty liver disease. Diabetes Metab Syndr Obes. 2019 March 12;12:315-324. doi: 10.2147/DMSO.S198744. PMID: 30881075; PMCID: PMC6420105.

Additional Files

Published

2025-11-17

How to Cite

Halder , S. ., Mishra, A., Pahari, S. ., Nansi, S. ., Chakrabarty, N. ., & Bhaduri, T. . (2025). Comprehensive Ayurvedic Management of Hepatic Fibrosis (Grade III): A Case Report . Journal of Ayurveda and Holistic Medicine (JAHM), 13(10), 108-117. https://doi.org/10.70066/jahm.v13i10.2288